Gen AI opportunities in Pharma

Related topics

In this episode of EY.ai Unplugged, Suresh Subramanian, National Life Sciences Leader, EY-Parthenon, discusses how AI is starting to reshape the Indian pharmaceutical sector. Drawing on EY research, he notes that over 65% of CEOs see AI as a key operational lever, with many already taking early steps. From faster drug discovery to smarter clinical trials, AI is no longer a future promise—it’s already in play.

Key takeaways:

AI’s transformative power: Pharma companies are moving beyond exploration—AI is now being piloted across critical functions like R&D, signaling a shift from potential to real-world impact.
Faster drug discovery: AI can reduce drug discovery timelines from months to weeks, accelerating innovation.
Efficiency in trials: One of the biggest benefits of AI is in enhancing efficiency and optimizing costs in development and clinical trials, from patient recruitment to data identification.
AI is here: AI is no longer a future concept — it is already shaping pharma operations today.

For your convenience, a full text transcript of this podcast is available on the link below:

Suresh

Artificial intelligence provides a great opportunity to transform and usher in a new era of innovation, in the Indian pharma.

Suresh

EY had recently conducted a research, wherein we found more than 65% of CEOs think of Artificial Intelligence and GenAI as impacting their operations significantly.

Suresh

Almost half of them had said, that they have started already, on a journey to integrate AI into their operations.

Suresh

Let's look at drug discovery and development. The process of discovery that takes many months can be done in a couple of weeks.

Suresh

Moving on to development and clinical trials, artificial intelligence can bring in much desired efficiency and optimization of costs, starting from recruitment of patients, identifying, you know, data sets.

Suresh

So, in summation, AI is not round the corner, it is there in our midst. It's there for you to take.

Presenters

Suresh Subramanian

National Life Sciences Leader, EY-Parthenon

If you would like to listen to our podcasts on the go:

Spotify

Podcast

Episode 20

Duration

2m 8s

AI Insights - AI Innovations & Transformation

Explore AI services & Insights at EY to drive innovation, improve efficiency & enable responsible AI adoption across industries with data-driven solutions.
Read more
Artificial Intelligence Consulting Services

Our Consulting approach to the adoption of AI and intelligent automation is human-centered, pragmatic, outcomes-focused and ethical.
Read more
EY R&D Workbench for Pharma

EY R&D Workbench for Pharma is a unique ERP solution that streamlines R&D, manufacturing, and compliance boosting speed, transparency, and efficiency.
Read more

In this series

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

EY-Parthenon is a brand under which a number of EY member firms across the globe provide strategy consulting services.